Cargando…

Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report

BACKGROUND: Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adjuvant che...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Meng-Lun, Besch, Brian M., Peterson, Jo Elle G., Henson, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533597/
https://www.ncbi.nlm.nih.gov/pubmed/36195921
http://dx.doi.org/10.1186/s13256-022-03596-0
_version_ 1784802378810130432
author Hsieh, Meng-Lun
Besch, Brian M.
Peterson, Jo Elle G.
Henson, Christina
author_facet Hsieh, Meng-Lun
Besch, Brian M.
Peterson, Jo Elle G.
Henson, Christina
author_sort Hsieh, Meng-Lun
collection PubMed
description BACKGROUND: Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adjuvant chemoradiation. CASE PRESENTATION: We report a rare case of primary squamous cell carcinoma of the thyroid in a 68-year-old White male who underwent chemoradiation and palliative immunotherapy after declining surgery. He was treated with intensity-modulated radiation therapy to 70 Gy in 35 fractions, with concurrent carboplatin–paclitaxel and palliative pembrolizumab. Local thyroid disease recurrence occurred at 6 months post-chemoradiation, and the patient died at 16 months post-chemoradiation. CONCLUSIONS: This is the first case report demonstrating the use of pembrolizumab as palliative therapy for primary squamous cell carcinoma of the thyroid. Our study also highlights the importance of chemoradiation in decreasing primary mass size and immunotherapy in preventing metastatic disease progression.
format Online
Article
Text
id pubmed-9533597
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95335972022-10-06 Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report Hsieh, Meng-Lun Besch, Brian M. Peterson, Jo Elle G. Henson, Christina J Med Case Rep Case Report BACKGROUND: Primary squamous cell carcinoma of the thyroid is a very rare malignancy with aggressive growth and poor prognosis. There is currently no consensus for treatment modality, however, most patients with primary squamous cell carcinoma of the thyroid are treated with surgery and adjuvant chemoradiation. CASE PRESENTATION: We report a rare case of primary squamous cell carcinoma of the thyroid in a 68-year-old White male who underwent chemoradiation and palliative immunotherapy after declining surgery. He was treated with intensity-modulated radiation therapy to 70 Gy in 35 fractions, with concurrent carboplatin–paclitaxel and palliative pembrolizumab. Local thyroid disease recurrence occurred at 6 months post-chemoradiation, and the patient died at 16 months post-chemoradiation. CONCLUSIONS: This is the first case report demonstrating the use of pembrolizumab as palliative therapy for primary squamous cell carcinoma of the thyroid. Our study also highlights the importance of chemoradiation in decreasing primary mass size and immunotherapy in preventing metastatic disease progression. BioMed Central 2022-10-05 /pmc/articles/PMC9533597/ /pubmed/36195921 http://dx.doi.org/10.1186/s13256-022-03596-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Hsieh, Meng-Lun
Besch, Brian M.
Peterson, Jo Elle G.
Henson, Christina
Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
title Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
title_full Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
title_fullStr Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
title_full_unstemmed Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
title_short Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
title_sort primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533597/
https://www.ncbi.nlm.nih.gov/pubmed/36195921
http://dx.doi.org/10.1186/s13256-022-03596-0
work_keys_str_mv AT hsiehmenglun primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport
AT beschbrianm primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport
AT petersonjoelleg primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport
AT hensonchristina primarysquamouscellcarcinomaofthethyroidtreatedwithconcurrentchemoradiationandpalliativeimmunotherapyacasereport